Back to Search
Start Over
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine
- Source :
- Clinical Gastroenterology and Hepatology, Clinical Gastroenterology and Hepatology, WB Saunders, 2021, 19 (6), pp.1180-1188.e4. ⟨10.1016/j.cgh.2020.08.001⟩, Clinical Gastroenterology and Hepatology, WB Saunders, 2020, 19 (6), pp.1180-1188. ⟨10.1016/j.cgh.2020.08.001⟩, Clinical Gastroenterology and Hepatology, 2021, 19 (6), pp.1180-1188.e4. ⟨10.1016/j.cgh.2020.08.001⟩
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- International audience; BACKGROUND/AIMS: Few data on the evolution of endoscopic findings are available in patients with acute severe ulcerative colitis (ASUC). The aim of this study was to describe this evolution in a prospective cohort. METHODS: Patients admitted for a steroid-refractory ASUC and included in a randomized trial comparing infliximab and cyclosporine were eligible if they achieved steroid-free clinical remission at day 98. Flexible sigmoidoscopies were performed at baseline, days 7, 42 and 98. Ulcerative colitis endoscopic index of severity (UCEIS) and its sub-scores - vascular pattern, bleeding and ulceration/erosion - were post-hoc calculated. Global endoscopic remission was defined by a UCEIS of 0, and partial endoscopic remission by any UCEIS sub-score of 0. RESULTS: Among the 55 patients analyzed (29 infliximab and 26 cyclosporine), 49 (83%) had UCEIS >= 6 at baseline at baseline. Partial endoscopic remission rates were higher for bleeding than for vascular pattern and for ulcerations/erosions at day 7 (20% vs. 4% and 5% (n = 55); p
- Subjects :
- medicine.medical_specialty
MAINTENANCE THERAPY
UCEIS
[SDV]Life Sciences [q-bio]
Gastroenterology
Severity of Illness Index
Mucosal Healing
law.invention
Vedolizumab
03 medical and health sciences
0302 clinical medicine
Maintenance therapy
Randomized controlled trial
law
Interquartile range
VEDOLIZUMAB
Internal medicine
medicine
Humans
Prospective Studies
Prospective cohort study
INDEX
OUTCOMES
Hepatology
business.industry
ulcerative Colitis
INDUCTION
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
REMISSION
medicine.disease
Ulcerative colitis
[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Infliximab
3. Good health
Treatment Outcome
030220 oncology & carcinogenesis
3121 General medicine, internal medicine and other clinical medicine
Cyclosporine
030211 gastroenterology & hepatology
Colitis, Ulcerative
Steroids
business
Steroid refractory
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 15423565
- Database :
- OpenAIRE
- Journal :
- Clinical Gastroenterology and Hepatology, Clinical Gastroenterology and Hepatology, WB Saunders, 2021, 19 (6), pp.1180-1188.e4. ⟨10.1016/j.cgh.2020.08.001⟩, Clinical Gastroenterology and Hepatology, WB Saunders, 2020, 19 (6), pp.1180-1188. ⟨10.1016/j.cgh.2020.08.001⟩, Clinical Gastroenterology and Hepatology, 2021, 19 (6), pp.1180-1188.e4. ⟨10.1016/j.cgh.2020.08.001⟩
- Accession number :
- edsair.doi.dedup.....a050d951c09073a8d47e45397af9f87e
- Full Text :
- https://doi.org/10.1016/j.cgh.2020.08.001⟩